Skip to page content

Adam J. Gordon — Publications

Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment 2023
Buprenorphine Treatment Episodes During the First Year of COVID: A Retrospective Examination of Treatment Initiation and Retention 2023
Expert Views on State Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder: A Qualitative Analysis of an Online Modified Delphi Process 2023
Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads 2023
National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018 2023
Prior Authorization Restrictions on Medications for Opioid Use Disorder: Trends in State Laws from 2005 to 2019 2023
Beyond State Scope of Practice Laws for Advanced Practitioners: Additional Supervision Requirements for Buprenorphine Prescribing 2022
Buprenorphine Treatment Episode Duration, Dosage, and Concurrent Prescribing of Benzodiazepines and Opioid Analgesics: The Effects of Medicaid Prior Authorization Policies 2022
Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder 2022
Laws for Expanding Access to Medications for Opioid Use Disorder: A Legal Analysis of 16 States & Washington D.C. 2022
Sociodemographic Differences in Quality of Treatment to Medicaid Enrollees Receiving Buprenorphine 2022
Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020 2022
Buprenorphine Prescriber Monthly Patient Caseloads: An Examination of 6-Year Trajectories 2021
Common Themes in Early State Policy Responses to Substance Use Disorder Treatment During COVID-19 2021
Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the U.S. 2021
Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes from a Review of State Laws 2021
A Population-Based Examination of Trends and Disparities in Medication Treatment for Opioid Use Disorders Among Medicaid Enrollees 2018
Opioid Analgesic and Benzodiazepine Prescribing Among Medicaid-enrollees with Opioid Use Disorders: The Influence of Provider Communities 2016
Physician Capacity to Treat Opioid Use Disorder with Buprenorphine-Assisted Treatment 2016
Growth in Buprenorphine Waivers for Physicians Increased Potential Access to Opioid Agonist Treatment, 2002-11 2015
Policies Related to Opioid Agonist Therapy for Opioid Use Disorders: The Evolution of State Policies from 2004 to 2013 2015
Policies to Support a Better Treatment for Heroin and Prescription Opioid Abuse: Unlike Methadone, Buprenorphine Can Be Taken at Home, but Greater Access is Key 2015
Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process 2015
Supply of Buprenorphine Waivered Physicians: The Influence of State Policies 2015
Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties 2015
The Impact of Buprenorphine on Treatment of Opioid Dependence in a Medicaid Population: Recent Service Utilization Trends in the Use of Buprenorphine and Methadone 2012